Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastrooesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial

被引：10
|
作者：
Zhang, X. [1 ]
Li, Z. [2 ]
Liang, H. [3 ]
Xue, Y. [4 ]
Wang, Y. [5 ]
Zhou, Z. [6 ]
Yu, J. [7 ]
Chen, L. [8 ]
Du, Y. [9 ]
Li, G. [10 ]
Xiao, G. [11 ]
Wu, D. [12 ]
Zhou, Y. [13 ]
Dang, C. [14 ]
He, Y. [15 ]
Zhang, Z. [16 ]
Sun, Y. [17 ]
Li, Y. [18 ]
Shen, L. [1 ]
Ji, J. [2 ]
机构：
[1] Peking Univ Canc Hosp, Dept Gastrointestinal Oncol, Beijing Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Gastrointestinal Canc Ctr, Beijing Canc Hosp, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Surg, Tianjin, Peoples R China
[4] Harbin Med Univ, Dept Surg, Canc Hosp, Harbin, Peoples R China
[5] Fudan Univ, Dept Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Sun Yat Sen Univ, Dept Surg, Canc Ctr, Guangzhou, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Sch Med, Hangzhou, Peoples R China
[8] Chinese Peoples Liberat Army Gen Hosp, Dept Surg, Mil Hosp 301, Beijing, Peoples R China
[9] Zhejiang Canc Hosp, Dept Surg, Hangzhou, Peoples R China
[10] East Theater Gen Hosp PLA, Dept Surg, Nanjing, Peoples R China
[11] Beijing Hosp, Dept Surg, Beijing, Peoples R China
[12] Zhejiang Univ, Dept Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
[13] Qingdao Univ, Dept Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[14] Xi An Jiao Tong Univ, Dept Surg, Affiliated Hosp 1, Xian, Peoples R China
[15] Sun Yat Sen Univ, Dept Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[16] Capital Med Univ, Beijing Friendship Hosp, Dept Surg, Beijing, Peoples R China
[17] Fudan Univ, Dept Surg, Zhongshan Hosp, Shanghai, Peoples R China
[18] Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA78
引用
收藏
页码：S1318 / S1319
页数：2
相关论文
共 50 条
  • [41] Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
    Wang, Yan
    Cheng, Xi
    Cui, Yue-hong
    Hou, Jun
    Ji, Yuan
    Sun, Yi-hong
    Shen, Zhen-bin
    Liu, Feng-lin
    Liu, Tian-shu
    BMC CANCER, 2018, 18
  • [42] Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study
    Jiang, Zhichao
    Sun, Yongkun
    Zhang, Wen
    Cui, Chengxu
    Yang, Lin
    Zhou, Aiping
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (03) : 180 - 186
  • [43] Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
    Yu, Yuanyuan
    Zhang, Zicheng
    Meng, Qianhao
    Ma, Yue
    Fan, Xiaona
    Sun, Jie
    Wang, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
    Kang, Yoon-Koo
    Kim, Hyung-Don
    Cho, Hyungwoo
    Park, Young Soo
    Lee, Jong Seok
    Ryu, Min-Hee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [45] Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial
    Kang, Yoon-Koo
    Kim, Hyung-Don
    Yook, Jeong Hwan
    Park, Young-Kyu
    Kim, Young-Woo
    Kim, Jin Young
    Ryu, Min-Hee
    Rha, Sun Young
    Chung, Ik-Joo
    Kim, In-Ho
    Oh, Sang Cheul
    Yoo, Chang Hak
    Kang, Seok Yun
    Zang, Dae Young
    Kim, Sunju
    Noh, Sung Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] The efficacy, safety and cell-free DNA of perioperative leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective phase II trial
    Yen, C. C.
    Chen, I. S.
    Chao, Y. J.
    Bai, L-Y.
    Tsai, C. Y.
    Jui, P.
    Hsu, C. Y.
    Liao, T. K.
    Huang, C-J.
    Liu, I. T.
    Shan, Y-S.
    Yen, C. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1474 - S1475
  • [47] Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study
    Yu, Pengfei
    Du, Yian
    Xu, Zhiyuan
    Yang, Litao
    Ying, Jieer
    Chen, Ping
    Wei, Yunhai
    Wu, Yingjie
    Zhang, Xiaojing
    Yan, Zhilong
    Chen, Zhiheng
    Xu, Hongtao
    Li, Yong
    Zheng, Zhichao
    Xu, Nong
    Cheng, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
    Jeong, Sang-Ho
    Kim, Rock Bum
    Oh, Sung Eun
    An, Ji Yeong
    Seo, Kyung Won
    Min, Jae-Seok
    CANCERS, 2022, 14 (16)
  • [49] Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
    Cheng, Xiangdong
    Wu, Dan
    Xu, Nong
    Chen, Luchuan
    Yan, Zhilong
    Chen, Ping
    Zhou, Lei
    Yu, Jianfa
    Cui, Jiuwei
    Li, Wei
    Wang, Chang
    Feng, Wenming
    Wei, Yunhai
    Yu, Pengfei
    Du, Yian
    Ying, Jieer
    Xu, Zhiyuan
    Yang, Litao
    Zhang, Yunli
    BMC CANCER, 2021, 21 (01)
  • [50] Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
    Xiangdong Cheng
    Dan Wu
    Nong Xu
    Luchuan Chen
    Zhilong Yan
    Ping Chen
    Lei Zhou
    Jianfa Yu
    Jiuwei Cui
    Wei Li
    Chang Wang
    Wenming Feng
    Yunhai Wei
    Pengfei Yu
    Yian Du
    Jieer Ying
    Zhiyuan Xu
    Litao Yang
    Yunli Zhang
    BMC Cancer, 21
12345